Expanding the DNA alphabet: ‘extra’ DNA base found to be stable
A rare DNA base, previously thought to be a temporary modification, has been shown to be stable in mammalian DNA, suggesting that it plays a key role in cellular function.
Researchers from the University of Cambridge and the Babraham Institute have found that a naturally occurring modified DNA base appears to be stably incorporated in the DNA of many mammalian tissues, possibly representing an expansion of the functional DNA alphabet.
The new study, published today in the journal Nature Chemical Biology, has found that this rare ‘extra’ base, known as 5-formylcytosine (5fC) is stable in living mouse tissues. While its exact function is yet to be determined, 5fC’s physical position in the genome makes it likely that it plays a key role in gene activity.
“If 5fC is present in the DNA of all tissues, it is probably there for a reason,” said Professor Shankar Balasubramanian of the Department of Chemistry and the Cancer Research UK Cambridge Institute, who led the research. “It had been thought this modification was solely a short-lived intermediate, but the fact that we’ve demonstrated it can be stable in living tissue shows that it could regulate gene expression and potentially signal other events in cells.”
Related News
See all news-
Dr Guiping Wang appointed as a Junior Group Leader
18th May 2026
Dr Guiping Wang joins the Cancer Research UK Cambridge Institute as a Junior Group Leader, starting in September 2026.
Find out more -
Shankar Balasubramanian receives the Princess of Asturias Award for Scientific and Technical Research
14th May 2026
The 2026 award recognises Prof Balasubramanian and his co-recipients David Klenerman and Pascal Meyer for their pioneering work in genome sequencing technologies.
Find out more -
Prof Sir Steve Jackson receives the 2026 Galen Medal in Therapeutics
14th May 2026
This award comes in recognition of his transformational work on the mechanisms of DNA repair, cell survival and the DNA-damage response (DDR), as well as for the development of the cancer-targeting drug Olaparib.
Find out more